Categories: 健康心血管病

Empagliflozin Reduced Cardiovascular Events and Mortality in Type 2 DiabetesEmpagliflozin降低了2型糖尿病心血管事件和死亡率

A randomized trial showed that empagliflozin (Jardiance), when added to standard care of patients with type 2 diabetes at high risk for cardiovascular events, reduced primary composite cardiovascular events and mortality from any cause. A total of 7020 patients were treated (median observation time, 3.1 years) with 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 10.5% in the pooled empagliflozin group and in 12.1% in the placebo group (P=0.04 for superiority). There were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group), hospitalization for heart failure (2.7% and 4.1%, respectively), and death from any cause (5.7% and 8.3%, respectively) in patients receiving empagliflozin, and there was an increased rate of genital infection but no increase in other adverse events. This is the first study showing that a diabetes drug has a clear cardiovascular benefit. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2. Source: http://www.nejm.org/

一项随机试验表明,在心血管事件高风险的2型糖尿病患者的标准治疗中加入empagliflozin(Jardiance),减少了主要复合心血管事件和全因死亡率。共收治7020例患者(中位观察时间,3.1年),10毫克或25毫克empagliflozin,或安慰剂,每天一次。汇总的empagliflozin组主要复合指标(死于心血管病,非致死性心梗,或非致死性卒中)发生了10.5%,而安慰剂组为12.1%(P = 0.04的优势)。接受empagliflozin者心血管病死亡率(3.7%,而安慰剂组为5.9%),因心衰住院(分别为2.7%和4.1%),以及全因死亡率(分别为5.7%和8.3%)均显著降低,而生殖器感染的发生率增加,但其他不良事件并未增加。这是第一次有研究显示,糖尿病药物对心血管明显有益。 Empagliflozin是钠葡萄糖共转体2的抑制剂。来源:http://www.nejm.org/

hyangiu

近期博文

4:3间歇性禁食减肥效果优于每日热量限制

一项美国随机临床试验发现,对于…

2 天 ago

新型降糖药对老年二型糖尿病患者心血管病的效果比较

一项丹麦全国性队列研究提供的真…

1 周 ago

非手术与非介入疗法对腰痛的疗效

基于安慰剂对照的随机试验,一项…

2 周 ago

服用他汀类药物与肝癌及肝病进展风险降低有关

一项美国队列研究提示,服用他汀…

2 周 ago

颈动脉斑块的临床意义及其与年龄和性别的关系

一项美国队列研究提示,在没有临…

3 周 ago

用植物油取代黄油可提高生存率

一项基于美国人群的前瞻性队列研…

4 周 ago

This website uses cookies.